RenovoRx and Imugene Announce Collaboration
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Source: briefingwire.com
Life Sciences Edition News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Life Sciences Edition. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Life Sciences Edition Today - Breaking & Trending Today
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platformTAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver
Source: prwire.com.au
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Source: newsmaker.com.au
Imugene will collaborate with RenovoRx to deliver oncolytic virus through proprietary TAMP platform
Immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF) has entered into a strategic research collaboration with clinical-stage biopharmaceutical RenovoRx,...
Source: proactiveinvestors.com
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMPâ„¢) Platform
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform.TAMP enables localized, targeted delivery of CF33 to...
Source: marketscreener.com